arvinas_logoART_lg.jpg
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
February 17, 2022 08:00 ET | Arvinas Inc.
– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses – – Data support the...
Vantage Market Research.png
Peptide Cancer Vaccine Market to Reach USD 10.07 Billion by 2028 - Vast Usage of Peptide Vaccine to Control Tumour Growth Propels the Market Demand – Vantage Market Research
February 15, 2022 03:33 ET | Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Peptide Cancer Vaccine Market finds that Peptide Cancer Vaccine aids to provide tumour-specific...
arvinas_logoART_lg.jpg
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
February 14, 2022 18:04 ET | Arvinas Inc.
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
February 07, 2022 18:08 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
February 03, 2022 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Global Oncology Precision Medicine Market
The Worldwide Oncology Precision Medicine Industry is Expected to Reach $64+ Billion by 2027
February 02, 2022 05:13 ET | Research and Markets
Dublin, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The "Worldwide Oncology Precision Medicine Industry" report has been added to ResearchAndMarkets.com's offering. This report provides a detailed analysis...
20170406 Telix Logo.png
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
January 26, 2022 16:51 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
Curium to become maj
Curium to become major player in the supply on non carrier added Lu-177
January 25, 2022 00:00 ET | Curium
London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...
Picture1.jpg
Curium to become major player in the supply on non carrier added Lu-177
January 25, 2022 00:00 ET | Curium
LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...
22157.jpg
Global Community Oncology Services Markets Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F
January 10, 2022 04:23 ET | Research and Markets
Dublin, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. ...